Poniard Pharmaceuticals (PARD) Stock Price, News & Analysis

Company Overview

Poniard Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the research and development of targeted therapies for oncology and immuno-oncology. The company’s scientific efforts center on small-molecule drug candidates designed to inhibit tumor growth pathways and enhance anti-tumor immune responses. Poniard seeks to address unmet medical needs by advancing novel mechanisms of action in cancer treatment, with an emphasis on selecting compounds that exhibit both efficacy and safety in preclinical studies.

Poniard’s product pipeline comprises lead candidates that have progressed through discovery and preclinical development, each aimed at modulating key signaling pathways involved in cancer cell survival and immune evasion. The company employs a combination of in-house research capabilities and external collaborations with academic laboratories to accelerate the identification and optimization of its therapeutic agents. This approach allows Poniard to leverage specialized expertise and cutting-edge technologies in assay development and medicinal chemistry.

Incorporated in Delaware and headquartered in Seattle, Washington, Poniard Pharmaceuticals operates primarily within the United States while evaluating opportunities for strategic partnerships abroad. The company’s leadership team brings together seasoned professionals in drug discovery, translational research, and clinical development, each contributing years of experience in advancing oncology programs from early-stage research through regulatory filings.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 323 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PARD Stock Analysis - Frequently Asked Questions

How do I buy shares of Poniard Pharmaceuticals?

Shares of PARD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Poniard Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Poniard Pharmaceuticals investors own include Plug Power (PLUG), Devon Energy (DVN), DOW (DOW), Chevron (CVX), Corteva (CTVA), Constellation Energy (CEG) and Brenmiller Energy (BNRG).

Company Calendar

• Today: 9/20/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:PARD
• CIK: 755806
• Web: www.poniard.com
• Phone: (206) 281-7001
• Fax: 650-583-3789
• Employees: 7
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 0.32